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Abstract
Background: Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues, including bone marrow,
adipose, and mucosa. MSCs have the capacity for self-renewal and differentiation. Reports have been published on
the systemic administration of MSCs leading to functional improvements by engraftment and differentiation, thus
providing a new strategy to regenerate damaged tissues. Recently, it has become clear that MSCs possess
immunomodulatory properties and can therefore be used to treat diseases. However, the therapeutic effect
mechanisms of MSCs are yet to be determined. Here, we investigated these mechanisms using a medication-
related osteonecrosis of the jaw (MRONJ)-like mouse model.
Methods: To generate MRONJ-like characteristics, mice received intravenous zoledronate and dexamethasone two
times a week. At 1 week after intravenous injection, maxillary first molars were extracted, and at 1 week after tooth
extraction, MSCs were isolated from the bone marrow of the mice femurs and tibias. To compare “diseased MSCs”
from MRONJ-like mice (d-MSCs) with “control MSCs” from untreated mice (c-MSCs), the isolated MSCs were
analyzed by differentiation and colony-forming unit-fibroblast (CFU-F) assays and systemic transplantation of either
d-MSCs or c-MSCs into MRONJ-like mice. Furthermore, we observed the exchange of cell contents among d-MSCs
and c-MSCs during coculture with all combinations of each MSC type.
Results: d-MSCs were inferior to c-MSCs in differentiation and CFU-F assays. Moreover, the d-MSC-treated group
did not show earlier healing in MRONJ-like mice. In cocultures with any combination, MSC pairs formed cell–cell
contacts and exchanged cell contents. Interestingly, the exchange among c-MSCs and d-MSCs was more frequently
observed than other pairs, and d-MSCs were distinguishable from c-MSCs.
Conclusions: The interaction of c-MSCs and d-MSCs, including exchange of cell contents, contributes to the
treatment potential of d-MSCs. This cellular behavior might be one therapeutic mechanism used by MSCs for
MRONJ.
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Background
Medication-related osteonecrosis of the jaw (MRONJ) is
defined as exposed necrotic bone in the oral cavity that
displays intractable symptoms which cannot be cured
for more than 8 weeks, and has never received radiation
treatment [1]. This condition appears to be nearly syn-
onymous with bisphosphonate-related osteonecrosis of
the jaw (BRONJ) [2]. Nitrogen-containing bisphospho-
nates (BPs) are widely used anti-bone resorptive medi-
cines, but they are well known to be associated with
osteonecrosis of the jaw (ONJ) [3]. The incidence of
MRONJ in cancer patients who have received high doses
of intravenous BPs, such as zoledronic acid, to inhibit
cancer invasion and migration is much higher than that
in patients receiving oral BP treatment for osteoporosis.
To date, even though several risk factors, including inva-
sive dental procedure, infection, mechanical trauma to
the jaw bone, and use of both immunosuppressive and
chemotherapy drugs, have connections with the onset of
MRONJ [4–6], the mechanisms remain largely un-
known. Additionally, because the etiology of MRONJ is
not clear the fundamental method of clinical treatment
for this disease is not recognized, and therefore novel
treatments are required for immediate worldwide
application.
Current symptomatic treatment of MRONJ involves
conservative clinical approaches, including antibiotics,
oral rinses, pain control, and limited debridement
with the aim of reducing the stage of necrosis. We
reported previously the positive effects of mesenchy-
mal stem cells (MSCs) for the treatment of MRONJ
[7, 8]. MSCs can self-renew and have the potential to
undergo multidirectional differentiation. MSCs can
differentiate into various lineages to secrete multiple
cytokines and growth factors and restore their sur-
rounding microenvironment. Therefore, MSCs have
great potential for clinical therapy and have many ap-
plications in various fields of regenerative medicine
[9]. Of significant interest, MSCs are now well docu-
mented to be immune-privileged [10] and secretory
cells of immunomodulatory factors [11, 12]. MSCs
clearly have an immune-regulatory capacity [13], dis-
playing immunosuppressive effects on certain condi-
tions. Therefore, MSCs have the potential to cure
inflammatory diseases. To date, the clinical applica-
tion of MSCs has focused mainly on their potential
for regenerative therapy, predominantly for myocar-
dium, bone marrow, skin, bone, and cartilage tissues.
More recently, however, immunomodulatory therapy
has been trialed and found to be successful for graft-
versus-host disease (GVHD), Crohn’s disease, aplastic
anemia, cirrhosis, and multiple sclerosis, following
systemic administration of MSCs. Indeed, MSCs have
a great potential for clinical prevention and treatment
of various autoimmune and inflammatory diseases.
However, the detailed mechanisms of MSC therapy
for any disease remain unknown, despite the large
amount of obtained clinical and experimental data.
Essentially, the therapeutic target in MSC therapy has
not been identified. Previous papers have reported MSC
abnormalities from ovarectomy (OVX), scleroderma,
and systemic lupus erythematosus (SLE) mouse models
[14–16]. MSC abnormalities include partial changes in
stemness, differentiation potential, proliferation, and col-
ony formation. In some cases, therefore, the application
of MSCs may worsen a patient’s condition. Namely, “dis-
ease treatment” may in fact mean “diseased MSC treat-
ment”, and therefore it seems comprehensive that
“diseased MSCs” (d-MSCs) are made the targets of
treatment.
The relationship between MSC-based therapy and
MSC function is not well understood. In this study, we
hypothesized that administered MSCs may influence the
host-diseased MSCs as the therapeutic target to act
more efficiently to treat the disease. To test this hypoth-
esis, we analyzed the therapeutic effect of MSCs with
various inflammatory properties using a MRONJ mouse
model to identify the mechanism of MSC therapy. This
study aimed to examine the effectiveness and mechan-
ism of MSC therapy for MRONJ, as well as investigating
the pathogenesis of this disease.
Methods
Animals
C57BL/6 N mice (male, 6 weeks old; Kyudo Lab, Tosu,
Japan) (n = 49) and GFP-transgenic C57BL/6 N mice
(CAG-EGFP) (male, 6 weeks old; Japan SLC, Shizuoka,
Japan) (n = 8) were used in this study. All animal experi-
ments were performed under an institutionally approved
protocol for the use of animal research at Kyushu
University (approval number: A25-124-0).
Generation of diseased mouse model
Mice received intravenous (i.v.) zoledronate (Zometa
(Zol), 125 μg/kg; Novartis Oncology, East Hanover, NJ,
USA) and dexamethasone (Dex, 10 mg/kg; Sigma, St.
Louis, MO, USA) twice a week via the tail vein. One
week after i.v. injection, maxillary first molars were ex-
tracted under systemic chloral hydrate and local lido-
caine hydrochloride (Abbott Laboratory, North Chicago,
IL, USA) anesthesia. One week after tooth extraction,
mice were sacrificed under systemic chloral anesthesia.
A total of five doses of Zol and Dex were administered.
Untreated mice with tooth extraction were used as a
control (n = 5) (Fig. 1a).
The intact maxilla, kidney, liver, lung, spleen, femur,
and tibia were harvested en bloc. In parallel, peripheral
blood was collected for cytokine analysis.
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ELISA of inflammation factors in blood
Peripheral blood was collected from the retro-orbital
plexus of mice and centrifuged to obtain the blood
serum [17]. Culture supernatants from MSCs were
collected [8]. MSCs were extracted using M-PER®
mammalian protein extraction reagent. The samples
were centrifuged and used in an enzyme-linked
immunosorbent assay (ELISA) for detection of
interleukin (IL)-2, IL-6 and IL-10 (R&D Systems,
Minneapolis, MN, USA).
Fig. 1 Multipotential differentiation of MSCs. a Experimental protocol for the in-vivo study. To isolate diseased MSCs (d-MSCs), wild-type C57BL/6 N
mice received both Dex and Zol administered intravenously for 2 weeks with tooth extraction. Control MSCs (c-MSCs) were isolated from normal mice,
which received no treatment (n = 4 × 2 groups). b (Top left) Osteogenic differentiation of MSCs. After culture under osteogenic differentiation
conditions for 4 weeks, osteogenic differentiation was determined by Alizarin Red S staining. Quantification of the Alizarin Red S dye content in
differentiated osteoblasts from independent experiments is shown (mean ± SD). Scale bar, 50 μm. (Top middle) Adipogenic differentiation of MSCs.
After culture under adipogenic differentiation conditions for 2 weeks, adipocyte differentiation was determined by Oil Red O staining. Zol treatment
decreased adipogenic differentiation of MSCs, as indicated by the decreased number of Oil Red O-positive cells (mean ± SD). *P < 0.05. (Top right)
Endothelial differentiation of MSCs. After culture under endothelial differentiation conditions for 2 weeks, differentiation was determined by the
formation of typical vessel-like-structures. Scale bar, 50 μm. (Bottom left) MSC migration determined by fluorescence microscopy. Larger numbers of
c-MSCs went through the transwell insert compared with d-MSCs. (Bottom middle) Rate of proliferation as determined by the EdU assay. The number
of EdU-positive cells was significantly decreased in the d-MSCs from the Zol-treated group compared with c-MSCs from the normal group. (Bottom
right) MSCs from normal mice generated fewer CFU-Fs compared with MSCs from MRONJ-like mice. CFU-F colony-forming unit-fibroblast, d days, EdU
5-ethynyl-2′-deoxyuridine, i.p. intraperitoneal, i.v. intravenous
Matsuura et al. Stem Cell Research & Therapy  (2016) 7:119 Page 3 of 11
Histomorphometry
After each experimental period, each organ was removed
from euthanized mice and immersed in 4 % paraformal-
dehyde (PFA; pH 7.4) for 2 days. The maxilla and femur
were then decalcified in 10 % tetrasodium ethylenedi-
aminetetraacetate (EDTA). All samples were dehydrated
in increasing concentrations of ethanol, embedded in
paraffin, and sectioned in the coronal plane. The sec-
tions were stained with hematoxylin and eosin (H & E).
Isolation and culture of MSCs
MSCs were isolated from the bone marrow of mice as
described previously [18]. Briefly, bone marrow cells
were flushed out of the mice femur and tibia bone cav-
ities. The cells were passed through a 40-μm cell strainer
to obtain a single cell suspension. The single cells were
seeded at 1 × 106 cells/dish in 100-mm culture dishes. At
1 day after seeding, the cells were washed with
phosphate-buffered saline (PBS) and cultured in growth
medium consisting of alpha-minimum essential medium
(α-MEM; Invitrogen, Grand Island, NY, USA) containing
20 % fetal bovine serum (FBS; Equitech-Bio, Kerrville,
TX, USA), 2 mM L-glutamine (Invitrogen), 100 U/ml
penicillin, and 100 μg/ml streptomycin (Invitrogen).
After 1 week of culture, the colony-forming unit-
fibroblasts (CFU-Fs) had formed colonies. The adherent
mesenchymal cells in these colonies were detached by
trypsin/EDTA (Invitrogen), reseeded as new cultures,
and expanded for further studies.
Osteogenic differentiation assay
MSCs (passage 2, 5 × 105 cells/dish) were grown on 35-mm
dishes to confluence in growth medium and then cul-
tured in osteogenic culture medium (growth medium
containing 1.8 mM KH2PO4 and 10 nM Dex; both
Sigma-Aldrich). After 28 days of osteogenic induction,
the cultures were stained with a 1 % Alizarin Red S solu-
tion (Sigma-Aldrich).
Adipogenic differentiation assay
MSCs (passage 2, 5 × 105 cells/dish) were grown on 35-mm
dishes to confluence in growth medium and then cultured
in adipogenic culture medium (growth medium containing
0.5 mM isobutylmethylxanthine, 60 μM indomethacin,
0.5 μM hydrocortisone, and 10 μg/ml insulin; all Sigma-
Aldrich). After 14 days of adipogenic induction, the cul-
tures were stained with Oil Red O. The Oil Red O-positive
lipid droplets were observed using an inverted microscope
(BZ-9000; Keyence, Osaka, Japan).
Angiogenesis assay
MSCs (passage 2, 5 × 105 cells/dish) were grown on 35-
mm dishes to confluence in growth medium and then
cultured in endothelial culture medium (growth medium
containing 0.5 mM isobutylmethylxanthine (Sigma-
Aldrich), 2 mM L-glutamine (Invitrogen), 55 μM 2-
mercaptoethanol (Invitrogen), 100 U/ml penicillin,
and 100 μg/ml streptomycin (Invitrogen)). After 14 days
of endothelial induction, the cultures were stained with
toluidine blue (Merck, Darmstadt, Germany). The for-
mation of capillary-like structures (CLS) was observed
using an inverted microscope.
Migration assay
MSCs (1 × 104) were seeded onto a FluoroBlok Insert
with an 8.0-μm pore size (Corning, Corning, NY, USA)
in a 24-well plate (BD Biosciences, Franklin Lakes, NJ,
USA). After 2 days of culture, MSCs on the bottom of
the FluoroBlok Insert were fixed with 4 % PFA (Merck)
for 5 minutes at room temperature, and then stained
with TRITC-phalloidin (1:400) for 2 hours. The cells
were washed with 1 % PBS and mounted with VECTA-
SHIELD Mounting Medium containing 4′,6-diamidino-
2-phenylindole (DAPI; Vector Laboratories, Burlingame,
CA, USA).
Proliferation assay
Cell proliferation was analyzed by a Click-iT® Plus EdU
Imaging Kit (Thermo Fisher Scientific, Waltham, MA,
USA). Cultured cells were exposed to 5-ethynyl-2′-deox-
yuridine (EdU) for 2 or 4 hours and then fixed in 4 %
PFA for 15 minutes followed by the inmation of a 0.5 %
Triton® X-100. Fixed cells were treated with the Click-iT®
reaction cocktail and phalloidin (1:100) for 15 minutes
and then mounted with DAPI-containing medium.
CFU-F assay
The CFU-F assay was performed as described previously
[19]. Passage 1 MSCs were seeded in culture dishes (Nalge
Nunc, Rochester, NY, USA). After 16 days of culture, the
cells were stained with a solution of 0.1 % toluidine blue
and 2 % PFA. Total colony numbers were counted per
dish. Three independent experiments were performed.
MSC injection
MSCs isolated from bone marrow were cultured and
passaged three times. These cells were injected (1 × 106
cells) into the mice with or without Dex/Zol via the tail
vein (n = 5 in each group) at 24 hours after tooth extrac-
tion. In the control group, the mice received PBS (n = 5).
Cell cultures
For in-vitro assessment, MSCs (2 × 104/dish) were
seeded into 35-mm dishes and incubated with or with-
out the other type of MSCs for 12 hours at 37 °C with
5 % CO2. Some MSCs were incubated in medium
containing 100 nM chloromethyltetramethylrodamine
(Mito, Mitotracker Orange CMTMRos; Molecular Probes,
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Eugene, OR, USA) for 20 minutes at 37 °C in the dark.
After three washes with medium, the cells were examined
under an inverted fluorescence microscope.
Tissue preparation
For in-vivo assessment, tissues were prepared according
to the methods described in our previous reports [20, 21].
At the end of each experimental period, mice were deeply
anesthetized and perfused intracardially with heparinized
PBS, followed by 4 % PFA (pH 7.4). The maxillae were
demineralized in 5 % EDTA for 4 days at 4 °C. The pre-
pared site was cut into 10-μm bucco-palatal sections with
a cryostat at −20 °C.
Immunohistochemistry
Immune-fluorescent staining of both in-vitro and in-
vivo samples was carried out as follows. Samples were
blocked with normal serum matched to secondary anti-
bodies for 1 hour followed by incubation with mouse
anti-rat green fluorescent protein (GFP) and CD90 anti-
bodies (1:100; Sigma-Aldrich) overnight at 4 °C. Slides
were then treated with FITC-conjugated secondary anti-
body (1:200; Jackson Immuno Research, West Grove,
PA, USA) for 1 hour at room temperature (RT) and
mounted with DAPI.
Statistical analysis
Data are expressed as means ± SD. One-way analysis of
variance with Fisher’s least-significant difference test was
performed. P < 0.05 was considered significant. Experi-
ments were performed using triplicate samples and were
repeated three or more times to verify their reproducibility.
Results
MRONJ-like mouse model
Figure 1a details the experimental schedules and
methods of our study. d-MSCs were isolated from the
bone marrow obtained from the femurs and tibias of
wild-type C57BL/6 N mice, which received both Dex
and Zol administered intravenously for 2 weeks. For the
control-MSCs (c-MSCs), the mice did not receive drug
treatment before MSC isolation.
Characteristics of d-MSCs
d-MSCs from MRONJ mice had a higher proliferation
rate compared with c-MSCs from normal mice, as
estimated by EdU exposure and CFU-Fs (Fig. 1b). In d-
MSCs, mineralized nodule formation stained by Alizarin
Red S and the number of Oil Red O-positive cells and
blood vessel-like structures per site/migrating cells were
decreased following treatment with Zol and Dex. These
data show that MRONJ disease is caused at the cellular
rather than tissue level, for example by MSCs.
Symptoms of the disease model and therapeutic efficacy
of MSCs
Figure 2b shows development of the MRONJ model and
the effects of MSCs on this model. Our experimental
data revealed incomplete mucosal healing and open
sockets with exposed bone in 80 % of mice treated with
a combination of Dex and Zol, but importantly no mice
treated with systemic MSCs showed incomplete mucosal
healing or open sockets with exposed bone.
Next, we investigated the effects of MSC treatment on
the levels of serum inflammatory cytokines, IL-2, IL-6,
and IL-10 in MRONJ mice. In this particular case,
MRONJ mice had higher IL-2 and IL-6 levels, and lower
IL-10 levels than the controls. Moreover, these inflam-
matory cytokine levels in the c-MSC(+) model were
similar to those in the controls. We identified abnormal-
ities in several organs, including the lung, kidney, liver,
and spleen, in the MRONJ model. All organs had obvi-
ous destruction of the typical structure, invasion of
inflammatory cells, and necrosis of components. Inter-
estingly, these inflammatory organ characteristics were
recovered by c-MSCs but not d-MSCs.
Development of MRONJ in these treated mice was
confirmed by a histological study that revealed a lack of
epithelial lining in the alveolar socket. Moreover, nec-
rotic bone was found adjacent to the area of intense in-
flammatory infiltrates, suggesting an association between
inflammation and tissue necrosis in MRONJ-like disease.
In contrast, 100 % of the MSC-treated mice showed
complete epithelial coverage, which was confirmed by
the histological study. In addition, abnormal MSCs from
disease model mice were converted to normal MSCs
after c-MSC treatment of MRONJ as shown in Fig. 4.
These data indicated that MRONJ was caused by abnor-
mal MSCs and could be recovered by treatment with
normal MSCs. These data indicated that a cumulative
dosage of Zol and Dex may be associated with the
occurrence of MRONJ in mice undergoing dental
extraction.
Accumulation of MSCs in the whole body
As shown in Fig. 3b, we investigated how intravenously
transplanted MSCs were able to influence endogenous
MSCs in mouse models or in patients. A number of dif-
ferent theories for the mechanism of MSC treatment
have been discussed. In a recent study, accumulating
MSCs at injured tissue sites in various diseases were
found to have direct contact with the injured cells, and
controlled the disorganization by promoting the repair
and regeneration of the cells and tissue. We therefore
decided to conduct the subsequent experiment to exam-
ine cell-to-cell contact of MSCs with other cell types.
We showed the ability of i.v. transplanted MSCs to
accumulate in various organs, including the dental
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extraction site. Many CD-90/GFP-FITC double-positive
cells had accumulated in the lung, liver, spleen, and
extraction site 1 day after MSC injection.
Intercellular exchange of MSCs
Some previous studies detail the transfection of mito-
chondria with microRNAs from MSCs to injured MSCs.
Based on this consideration, we hypothesized that mito-
chondria were important for the therapeutic abilities of
MSCs to regulate or cure injured cells. The next experi-
ment investigated whether mitochondria have any rela-
tionship with MSC therapy. Figure 5 shows in-vitro
analysis of d-MSCs and c-MSCs with red-stained
mitochondria in direct coculture with GFP-expressing c-
MSCs or d-MSCs, respectively. Interestingly, the red-
stained mitochondria from c-MSCs were observed to ac-
tively move to d-MSCs. This result was consistent with
the in-vivo study. As shown in Fig. 6b, many CD90(+)
and GFP(−) cells with stained mitochondria were located
in the upper portion of the socket. These results
indicated mitochondrial exchange between exogenous
and endogenous MSCs in MRONJ model mice. These
data therefore indicate that MSCs may be able to cure
d-MSCs via mitochondrial exchange.
Discussion
In this study, establishment of the MRONJ mouse model
was carried out based on our previous report [7]. Be-
cause MRONJ is associated with high doses of BPs, Zol
was administered at a dose at least 10 times greater than
Fig. 2 Epithelial healing after tooth extraction in a histological study. a Experimental protocol for the in-vivo experiments. Wild-type C57BL/6 N mice
received both dexamethasone (Dex) and zoledronate (Zol) administered intravenously for 2 weeks. c-MSCs or d-MSCs were injected into the mice a
day after tooth extraction (c-MSC(+) and d-MSC(+)). Control mice received no treatment and MRONJ mice received both Dex and Zol but had no MSC
treatment. b MRONJ model mice without treatment and with diseased MSCs had a lack of epithelial lining in the alveolar socket. In contrast, 100 % of
the MSC-treated mice showed complete epithelial coverage, which was confirmed by the histological study. Moreover, MRONJ mice had higher IL-2
and IL-6 levels, and lower IL-10 levels than the controls. Inflammatory cytokine levels of the c-MSC(+) model were similar to those of the controls. The
lung, kidney, liver, and spleen of the MRONJ model had obvious destruction of the typical structure, invasion of inflammatory cells, and necrosis of
components. These inflammatory organ characteristics were recovered by c-MSCs but not d-MSCs. n = 5 × 4 groups. c-MSC control MSC, d days, d-MSC
diseased MSC, i.p. intraperitoneal, i.v. intravenous, MRONJ medication-related osteonecrosis of the jaw, MSC mesenchymal stem cell
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that used for humans to efficiently induce MRONJ
(Fig. 1). Furthermore, the incidence of MRONJ-like dis-
ease in mice is enhanced by the combination of BP and
Dex compared with Zol alone [7, 22]. Our method
therefore ensured development of MRONJ to investigate
clinical treatments.
To verify the development of MRONJ in our mouse
model, maxillary bones were evaluated for clinical symp-
toms of MRONJ (Fig. 2), based on guidelines established
by the American Association of Oral and Maxillofacial
Surgeons and the American Society for Bone and
Mineral Research [1]. MRONJ model mice with open
sockets and exposed bone were further assessed for
MRONJ development using histological and biochemical
methods to detect increased inflammation (Fig. 2). These
procedures were carried out in a similar manner to a
previous study in which inflammatory cells and necrotic
bone areas with empty lacunae, fibrosis, and a lack of
epithelial lining overlaid areas of dead bone [23].
Moreover, as shown in Figs. 2b and 4b, d-MSCs from
MRONJ mice had abnormalities compared with c-MSCs
from normal mice, and the d-MSCs recovered after
MSC therapy. These data showed that MRONJ disease
occurs at the cellular level rather than the tissue level
and can be treated by cellular therapy such as MSC ther-
apy. Although MSCs were originally isolated from bone
marrow [9, 24] they are present in many other tissues
owing to their perivascular location, including adipose,
liver, lung, skeletal muscle, kidney, gingival, and dental
pulp tissues [25]. Previous reports show that the effect
of systemic MSC administration is affected by the cell
source, recipient age, sex, and health status [26, 27].
Moreover, it has been reported that abnormal MSCs are
observed in disease models as shown in Figs. 1b, 2b, and
4b. More recently, differences in MSC characteristics
have been investigated under each recipient condition.
For example, MSCs obtained from females exhibit a
higher proliferation rate than those from males [28].
Although MSCs have been shown to exert an inhibitory
effect on cancer cells [29], some reports show that MSCs
themselves promote the progression of disease symp-
toms in experimental mice [8, 30, 31], as shown in
Fig. 2b. Thus, there appears to be a strong interaction
between the recipient condition and the characteristics
of their MSCs.
Our study showed MSC abnormalities in the MRONJ
model, and MSC recovery in the MSC-treated model
was confirmed to be similar to that of normal MSCs
Fig. 3 Accumulation of GFP-transgenic injected MSCs into diseased mice. a Experimental protocol for the in-vivo experiments. Wild-type C57BL/6
N mice received both Dex and Zol administered intravenously. MSCs from GFP-transgenic mice were injected into the mice 1 day after tooth
extraction. b In various organs and around the extraction site, injected MSCs (CD-90/GFP-FITC double-positive cells) selectively accumulated into
the connective tissue close to the blood vessels. However, no double-positive MSCs were observed in the kidney and gingival mucosa. Scale
bar, 100 μm. n = 5 × 2 groups. c-MSC control mesenchymal stem cell, d days, d-MSC diseased mesenchymal stem cell, GFP green fluorescent
protein, i.p. intraperitoneal, i.v. intravenous. The right panel showed graphially the number of GFP and CD90 positive cells in each organs. Bars
represent the mean ± SD of six independent experiments. *P<0.05
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(Fig. 5). The administered MSCs therefore normalized
the d-MSCs in the diseased tissue and improved the dis-
eased environment by exerting therapeutic effects. At
present, mechanisms of such therapeutic effects are be-
ing investigated. Some studies suggest that administered
MSCs affect organs directly, while other studies indicate
that administered MSCs secrete growth factors and cyto-
kines that act indirectly through a paracrine mechanism.
To more clearly identify the specific mechanism, we fo-
cused on mitochondrial exchange among MSCs. A re-
cent study showed that accumulation of MSCs in the
damaged tissue sites of various diseases results in direct
contact with the injured cells, control of disorganization,
and promotion of repair and regeneration [32].
Furthermore, transfer of mitochondria with microRNAs
from MSCs to injured cells has been reported. This find-
ing indicates that mitochondria are important for self-
renewal and differentiation of MSCs [33, 34]. Indeed,
mitochondria have a characteristic ultrastructure and
play a role in cell behavior. Some reports show that the
differentiation potential of cells depends on the location
of mitochondria [34, 35]. Furthermore, different cell
types display different mitochondrial arrangements. For
example, fibroblastic cells display more mature elon-
gated mitochondria [36]. Folmes et al. [37] reported that
reprogramming of cells to induced pluripotent stem cells
results in mitochondrial rejuvenation. Moreover, mito-
chondria are exchanged between cells [38]. As shown in
Fig. 4 Characteristics of MSCs from MRONJ mice treated with MSCs. a Experimental protocol. Wild-type C57BL/6 J mice received both Dex and
Zol administered intravenously for 2 weeks (n = 5 × 2 groups). MSCs were isolated from MRONJ model mice treated with c-MSCs or d-MSCs a day
after tooth extraction (M-cMSC and M-dMSC(+)). b MSC abnormalities in MRONJ were reversed by c-MSCs but not d-MSCs. CFU-F colony-forming
unit-fibroblast, c-MSC control MSC, d days, d-MSC diseased MSC, EdU 5-ethynyl-2′-deoxyuridine, i.p. intraperitoneal, i.v. intravenous, MRONJ
medication-related osteonecrosis of the jaw, MSC mesenchymal stem cell
Matsuura et al. Stem Cell Research & Therapy  (2016) 7:119 Page 8 of 11
Fig. 6b, MSCs with mitochondria stained immediately
before injection were transplanted into GFP-transgenic
mice. After 2 days, the targeted organs with accumula-
tion of MSCs were removed. In this experiment, adja-
cent continuous sections were considered to be the
same section. One section was stained with an anti-GFP
antibody and the adjacent section was stained with an
antibody against MSC marker CD90. Host MSCs were
thus distinguished from other cells. Transfer of mito-
chondria to endogenous MSC from transplanted MSCs
was indicated by CD90(+) and GFP(−) MSCs in serial
sections with red-stained areas of mitochondria. As a
result, many CD90(+) and GFP(−) cells with stained
mitochondria were located in the upper portion of the
socket. Indeed, these results showed mitochondrial
transfer from exogenous to endogenous MSCs in
MRONJ model mice. These findings and previous re-
ports suggest the importance of mitochondrial charac-
teristics in cell differentiation and reprogramming.
Mitochondrial characteristics appear to dictate cellular
Fig. 5 Intercellular exchange of MSCs. a Explanatory schema of the various MSCs in this experiment (n = 3 × 4 groups). b Experimental protocol
for the in-vitro experiments. d-MSCs were cocultured with c-MSCs or d-MSCs for 24, 48, and 72 hours to analyze intercellular exchanges between
MSCs. c Typical image of MSCs with mitochondria exchange. MSC-GFP(+), green; MSC-mito(+), red. d, e d-MSCs stained (red) for visualization of
mitochondria were placed into direct coculture with c-MSCs stained with GFP (green). The mitochondria from the c-MSCs moved actively to the
d-MSCs. Scale bar, 50 μm. White arrows show the intercellular exchanges in early stage. c-MSC control MSC, DAPI 4′,6-diamidino-2-phenylindole, d-MSC
diseased MSC, GFP green fluorescent protein, i.p. intraperitoneal, i.v. intravenous, MRONJ medication-related osteonecrosis of the jaw, MSC mesenchymal
stem cell
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characteristics. However, the converse does not appear
to be true. Therefore, it is possible that MSCs repair
damaged cells by exchanging mitochondria [39]. Indeed,
because a lot of organelles including a membrane pro-
tein complex were transferred with mitochondria, these
contents should be also focused on the regulatory mech-
anism of erythropoiesis, biology, and clinical application
of MSCs. However, one possibility is that mitochondria
may participate in the treatment of host MSCs following
administration of MSCs.
Conclusions
Cell-based immunotherapy using systemic MSCs can
potentially offer a safe and effective therapeutic modality
in preventing the development of MRONJ disease. Fur-
thermore, the mechanism of MSC treatment for MRONJ
was shown to be the ability of transplanted MSCs to
directly control and regulate d-MSCs in the patients.
Moreover, mitochondria in the MSCs may play an im-
portant role in MSC regulation.
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Fig. 6 Intercellular exchange between endogenous and exogenous MSCs. a Experimental protocol for the in-vivo experiments. Wild-type
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